Population
Patients receiving anthracycline chemotherapy
Design
Review
Authors
Loading...
May inform cardioprotective targets; leaves open prospective validation of biomarkers before clinical adoption.
This review provides an update on the cellular mechanisms, signaling pathways, and biomarkers associated with anthracycline-induced cardiotoxicity.
Nebigil et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: